Telehealth weight management · Provider sources reviewed

CoreAge Rx: weight-loss provider profile

CoreAge Rx offers online prescribing assessment for compounded semaglutide and tirzepatide. Read the selected offer, total payment, clinical access and fulfillment rules together.

Sources checked October 4, 2026 · Public-source research

Current findings for CoreAge Rx

CoreAge Rx GLP-1 payment and offer diagram
Editorial diagram of public offer terms; confirm the selected order.

Two public prices and the lowest annual quote

CoreAge’s current product pages display $99 for semaglutide and $149 for tirzepatide. The lowest annual quotes supplied to this publication are $79 and $129 per month, corresponding to $948 and $1,548. Those figures describe different offers or payment terms; the selected checkout is the reference for what you would pay.

A starting number does not identify the prescribed preparation, supplied quantity or next renewal. Confirm those details before paying, including any laboratory or appointment charges. The public pages advertise no separate membership fee and free shipping.

What happens between intake and a prescription

The platform describes a health questionnaire followed by physician assessment. Treatment depends on that clinician’s decision. Completing a purchase or questionnaire is not a guarantee of a prescription, and a provider’s website does not verify the credentials of the person assigned to you.

The company advertises ongoing provider access. Ask which channel handles prescription questions and dose changes, how refills are requested and what happens outside normal support hours. This review has not measured response times, delivery or patient outcomes.

Refunds change once work has started

CoreAge’s refund policy distinguishes assessment, pharmacy fulfillment and shipping. It states that canceling future renewals does not automatically cancel a prescription already being filled. Depending on the treatment, a $50–$100 consultation charge may remain non-refundable after clinical review begins, including when a clinician declines treatment.

For your selected order, ask which portion is refundable, when pharmacy fulfillment starts and how to cancel a later renewal. A refund on the medication portion and a refund of every payment are different promises.

Pharmacy and preparation remain prescription-specific

Ask for the exact formulation, concentration and dispensing pharmacy. The reviewed offer does not establish a pharmacy audit or equivalence to an approved product. The clinician and pharmacist should explain why the proposed preparation is appropriate and how to use that prescription.

The published information describes an access pathway. It is not evidence that this publication enrolled as a patient, inspected medicine batches or verified a clinical result.

Understand the medication before comparing providers

Approved weight-management options include Wegovy (semaglutide), Zepbound (tirzepatide) and Foundayo (orforglipron), each with its own indication, formulation and instructions. Ozempic and Mounjaro are diabetes brands. The current provider findings above identify what could be verified about this company; this general comparison does not establish that it offers every named medicine.

Wegovy has injectable and oral formulations, Zepbound is injectable, and Foundayo is oral. A compounded or dissolvable product is not the approved branded product. Identify the exact prescription and route before comparing price or applying a trial result.

Compounded medicines are not FDA-approved. FDA recommends them only when a patient’s medical needs cannot be met by an approved medicine. Its April 2026 update says semaglutide and tirzepatide are not on the drug shortage list or the 503B bulks list. Patient-specific exceptions and other legal conditions matter; a “personalized” label, vitamin additive, or pharmacy registration does not by itself establish compliance or effectiveness.

Safety questions for the prescribing clinician

The approved products cited here have a boxed warning about thyroid C-cell tumors in rodents; whether they cause these tumors in humans is unknown. Their contraindications include a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and specified serious allergic reactions. These are specific conditions, rather than a statement that every thyroid disorder rules out treatment. Review the exact product label with your clinician.

Tell the clinician about severe stomach-emptying problems, pancreatitis or gallbladder history, kidney concerns, diabetic eye disease, and every medicine or supplement you use. The labels do not recommend these products in severe gastroparesis. Insulin and medicines such as sulfonylureas can increase low-blood-sugar risk when used with them; adjustments belong with the prescriber. These examples do not replace the full safety review.

For weight management, Wegovy should be discontinued when pregnancy is recognized, and its label calls for stopping at least two months before a planned pregnancy. Ozempic also specifies at least two months before a planned pregnancy. Discuss the plan before trying to conceive. Wegovy tablets are not recommended during breastfeeding; the injection requires its own benefit-and-risk discussion.

Zepbound should be discontinued when pregnancy is recognized. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives: the Zepbound and Mounjaro labels advise a non-oral method or an added barrier method for four weeks after starting and for four weeks after each dose increase. Ask the clinician about pregnancy planning and breastfeeding for the exact prescription.

Foundayo also calls for discontinuation when pregnancy is recognized. Its oral-contraceptive precautions use 30 days after starting and 30 days after each dose increase. It is not recommended for nursing women. Do not substitute one product’s contraception or pregnancy instructions for another’s.

Severe abdominal pain that does not go away, with or without vomiting, can be a pancreatitis warning; the labels instruct patients to stop the medicine and seek medical help promptly. Repeated vomiting or inability to keep fluids down also needs prompt assessment. For trouble breathing or swallowing, swelling of the face, tongue or throat, or collapse suggesting a serious allergic reaction, call 911 or your local emergency number immediately. Your provider should explain urgent and after-hours care before treatment starts.

Tell the anesthesia or procedure team about treatment before surgery or deep sedation. Do not independently combine GLP-1 products, shorten injection intervals or restart an old high dose after a break. Procedure planning and side effects and warning symptoms explain the questions to resolve with the care team.

Questions to resolve before paying CoreAge Rx

  • Which exact medication and formulation would my prescription specify, and which pharmacy would dispense it?
  • What are the total first and renewal payments, and does the advertised monthly price require prepayment?
  • Who manages side effects and dose changes, and what follow-up care is included?
  • What is the cancellation deadline, and which fees remain non-refundable?

Ask for a written quote showing the medication, care or membership fee, labs, shipping, supplies, first payment, renewal payment, and cancellation cutoff. A monthly equivalent on a prepaid plan is different from paying that amount every month. A four-week supply and a calendar-month subscription also have different annual totals.

Verify your prescriber’s license and the dispensing pharmacy with the relevant state boards. Check that the pharmacy named on your prescription matches the pharmacy on the package. If injectable medication arrives warm or inadequately refrigerated, FDA advises against using it; contact the dispensing pharmacy for instructions. Avoid products sold as research chemicals or without a prescription.

How to use this profile

This is a review of public information, not a hands-on clinical test or a verified patient review. We do not assign star ratings to clinical care, medication quality, response time, or shipping. An advertised benefit remains a provider claim unless independent evidence supports the specific claim. Confirm current availability, state eligibility, and the final terms directly before enrolling.

Read our source and correction policy and commercial disclosure. Medical review has not been completed.

Sources and verification

Provider pages document what a company advertises. Prescribing information and regulator guidance support medical and regulatory claims. Reviewing a website does not verify its clinical service, pharmacy quality, or your eligibility.

  1. CoreAge Rx: semaglutide product and offer
    provider · Text reviewed · Checked October 4, 2026
  2. CoreAge Rx: tirzepatide product and offer
    provider · Text reviewed · Checked October 4, 2026
  3. CoreAge Rx: refunds, consultation fees, subscriptions and shipping
    provider · Text reviewed · Checked October 4, 2026
  4. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
    regulator · Text reviewed · Checked October 2, 2026
  5. Wegovy prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  6. Ozempic prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  7. Zepbound prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  8. Mounjaro prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  9. Foundayo prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  10. Anaphylaxis: MedlinePlus Medical Encyclopedia
    clinical guidance · Text reviewed · Checked October 2, 2026
  11. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
    regulator · Text reviewed · Checked October 4, 2026